These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23053272)

  • 41. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation.
    Oblon DJ; Paul SR; Oblon MB; Malik S
    Bone Marrow Transplant; 1997 Dec; 20(11):961-3. PubMed ID: 9422475
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
    Ikuta K; Fujioka K; Sumita H; Takahashi H; Sekiguchi H; Kai S; Kajigaya Y; Funabiki T; Sakai H; Matsuyama S
    Rinsho Ketsueki; 1993 May; 34(5):636-42. PubMed ID: 8100284
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.
    Ayas M; Al-Seraihi A; Al-Mahr M; Al-Jefri A; Belgaumi A; Elhassan I; El-Solh H
    Pediatr Blood Cancer; 2006 Dec; 47(7):926-30. PubMed ID: 16425264
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.
    Bunin N; Aplenc R; Kamani N; Shaw K; Cnaan A; Simms S
    Bone Marrow Transplant; 2003 Sep; 32(6):543-8. PubMed ID: 12953124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission.
    Biagi E; Rovelli A; Balduzzi A; De Lorenzo P; Tagliabue A; Uderzo C
    Bone Marrow Transplant; 2000 Dec; 26(11):1260-2. PubMed ID: 11149746
    [No Abstract]   [Full Text] [Related]  

  • 48. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
    Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR
    Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
    Sandler ES; Hagg R; Coppes MJ; Mustafa MM; Gamis A; Kamani N; Wall D
    Med Pediatr Oncol; 2000 Oct; 35(4):403-9. PubMed ID: 11025470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
    Wachowiak J; Bettoni C; Lange A; Malicki J; Kaczmarek-Kanold M; Głuszak B; Suchnicki K; Daszkiewicz P; Ebell W
    Acta Haematol Pol; 1995; 26(4):377-84. PubMed ID: 8571739
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
    Kirschbaum MH; Stein AS; Popplewell L; Delioukina M; Chen R; Nakamura R; Snyder D; Conrad J; Lacey SF; Frankel P; Dagis A; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):432-40. PubMed ID: 21801703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
    Carpenter PA; Marshall GM; Giri N; Vowels MR; Russell SJ
    Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
    Matsue K; Tohi T; Masauji N; Tsukuda K
    Rinsho Ketsueki; 1992 Mar; 33(3):338-42. PubMed ID: 1578638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
    Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
    Belkacémi Y; Ozsahin M; Rio B; Laporte JP; Leblond V; Pène F; Laugier A
    Strahlenther Onkol; 1995 Dec; 171(12):694-7. PubMed ID: 8545791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
    Petersen FB; Buckner CD; Appelbaum FR; Sanders JE; Bensinger WI; Storb R; Deeg HJ; Witherspoon RP; Sullivan KM; Clift RA
    Bone Marrow Transplant; 1992 Jul; 10(1):83-8. PubMed ID: 1515884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
    Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
    Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
    Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
    Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.